- About Us
- Research & Pipeline
- Investor Centre
- Media Centre
Our CEO, Dr James Garner recently conducted video and print interviews with Share Café following the US Food and Drug Administration’s award of Rare Pediatric Disease Designation for paxalisib in Diffuse Intrinsic Pontine Glioma (DIPG) and Fast Track Designation for paxalisib in glioblastoma.
In the interviews, Dr Garner discusses these significant milestones as well as Kazia’s upcoming participation in the pivotal GBM AGILE study – which will be used to seek marketing authorisation for paxalisib in glioblastoma – and the next steps for Kazia.
Read the print article here: https://www.sharecafe.com.au/2020/08/24/with-a-ticket-to-ride-kazia-wows-investors-with-its-rare-cancer-story/
View the video interview below: